Company intelligence / Profile preview

Kashiv BioSciences

Piscataway, New Jersey, United Stateskashivbiosciences.com ↗
Ownership
Private
Employees
~300
Development stage
Commercial
01

Overview

Kashiv BioSciences has achieved Health Canada approval for its Pegfilgrastim Injection (“Pexegra”), a G-CSF biosimilar now commercially available in Canada. Its omalizumab biosimilar candidate ADL‑018 has been accepted for review by the UK MHRA. The abatacept biosimilar KSHB002 reported successful Phase 1 results in early 2025. The company maintains a robust pipeline of advanced clinical and commercial-stage assets focused on expanding access to high-quality biologic medicines globally

Therapeutic areas
OncologyImmunology
Modalities
Monoclonal antibodies (mAbs)complex proteins/biologicsbiosimilarspeptide-based medicines
Industry
Biotech
02

Drug pipeline

14 assets

adl018

3

13 more assets in the full pipeline.

Request access →
03

Partnerships

JAMP Pharma Group—Canadian commercialization partner for Pegfilgrastim Injection (“Pexegra”)GoldenTree Asset Management—$150M debt financing partner supporting expansion efforts

Beyond the preview

Go deeper on Kashiv BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kashiv BioSciences.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call